In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was achieved with minimal disruption and substantial cost saving to our healthcare partners.
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...